DE69729209D1 - Humanisierte anti-koerper gegen cd11a - Google Patents
Humanisierte anti-koerper gegen cd11aInfo
- Publication number
- DE69729209D1 DE69729209D1 DE69729209T DE69729209T DE69729209D1 DE 69729209 D1 DE69729209 D1 DE 69729209D1 DE 69729209 T DE69729209 T DE 69729209T DE 69729209 T DE69729209 T DE 69729209T DE 69729209 D1 DE69729209 D1 DE 69729209D1
- Authority
- DE
- Germany
- Prior art keywords
- humanized anti
- body against
- against cd11a
- cd11a
- humanized
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Lifetime
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2839—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the integrin superfamily
- C07K16/2845—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the integrin superfamily against integrin beta2-subunit-containing molecules, e.g. CD11, CD18
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
- C12N15/62—DNA sequences coding for fusion proteins
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/55—Fab or Fab'
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2799/00—Uses of viruses
- C12N2799/02—Uses of viruses as vector
- C12N2799/021—Uses of viruses as vector for the expression of a heterologous nucleic acid
- C12N2799/022—Uses of viruses as vector for the expression of a heterologous nucleic acid where the vector is derived from an adenovirus
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Engineering & Computer Science (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Pharmacology & Pharmacy (AREA)
- General Chemical & Material Sciences (AREA)
- Genetics & Genomics (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Biomedical Technology (AREA)
- Immunology (AREA)
- Molecular Biology (AREA)
- Zoology (AREA)
- Wood Science & Technology (AREA)
- General Engineering & Computer Science (AREA)
- Biotechnology (AREA)
- Biophysics (AREA)
- Biochemistry (AREA)
- Physics & Mathematics (AREA)
- Plant Pathology (AREA)
- Pulmonology (AREA)
- Microbiology (AREA)
- Dermatology (AREA)
- Neurosurgery (AREA)
- Pain & Pain Management (AREA)
- Physical Education & Sports Medicine (AREA)
- Rheumatology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Neurology (AREA)
- Transplantation (AREA)
- Peptides Or Proteins (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US75720596A | 1996-11-27 | 1996-11-27 | |
US757205 | 1996-11-27 | ||
PCT/US1997/019041 WO1998023761A1 (en) | 1996-11-27 | 1997-10-20 | HUMANIZED ANTI-CD11a ANTIBODIES |
Publications (2)
Publication Number | Publication Date |
---|---|
DE69729209D1 true DE69729209D1 (de) | 2004-06-24 |
DE69729209T2 DE69729209T2 (de) | 2005-05-19 |
Family
ID=25046834
Family Applications (3)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
DE200412000047 Pending DE122004000047I1 (de) | 1996-11-27 | 1997-10-20 | Humanisierte anti-koerper gegen cd11a. |
DE69729209T Expired - Lifetime DE69729209T2 (de) | 1996-11-27 | 1997-10-20 | Humanisierte anti-koerper gegen cd11a |
DE1997629209 Active DE122004000047I2 (de) | 1996-11-27 | 1997-10-20 | Humanisierte anti-koerper gegen CD11A |
Family Applications Before (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
DE200412000047 Pending DE122004000047I1 (de) | 1996-11-27 | 1997-10-20 | Humanisierte anti-koerper gegen cd11a. |
Family Applications After (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
DE1997629209 Active DE122004000047I2 (de) | 1996-11-27 | 1997-10-20 | Humanisierte anti-koerper gegen CD11A |
Country Status (17)
Country | Link |
---|---|
EP (2) | EP1516629B1 (de) |
JP (2) | JP3778945B2 (de) |
KR (1) | KR100532178B1 (de) |
AR (1) | AR008919A1 (de) |
AT (1) | ATE267257T1 (de) |
AU (1) | AU731817C (de) |
CA (1) | CA2272842C (de) |
DE (3) | DE122004000047I1 (de) |
DK (2) | DK1516629T3 (de) |
ES (1) | ES2221045T3 (de) |
FR (1) | FR04C0028I2 (de) |
IL (3) | IL130143A0 (de) |
LU (1) | LU91122I2 (de) |
NL (1) | NL300163I2 (de) |
PT (1) | PT941344E (de) |
WO (1) | WO1998023761A1 (de) |
ZA (1) | ZA979599B (de) |
Families Citing this family (73)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US7122636B1 (en) | 1997-02-21 | 2006-10-17 | Genentech, Inc. | Antibody fragment-polymer conjugates and uses of same |
JP2002530081A (ja) | 1998-11-18 | 2002-09-17 | ジェネンテック・インコーポレーテッド | 親抗体より高度な結合親和性を持つ抗体変異体 |
EP1950300A3 (de) | 1998-11-18 | 2011-03-23 | Genentech, Inc. | Antikörpervarianten mit höherer Bindungsaffinität im Vergleich zu verwandten Antikörpern |
DE60042735D1 (de) * | 1999-03-19 | 2009-09-24 | Genentech Inc | Behandlung von lfa-1 assozieerten krankheiten durch gesteigerte dosen von lfa-1 antagonist |
US6582698B1 (en) | 1999-03-19 | 2003-06-24 | Genentech, Inc. | Treatment method |
ES2311483T3 (es) * | 1999-12-14 | 2009-02-16 | Genentech, Inc. | Anatagonista del tnf-alfa y antagonista del lfa-1 para el tratamiento de la artritis reumatoide. |
US7560275B2 (en) | 1999-12-30 | 2009-07-14 | Vbi Technologies, L.L.C. | Compositions and methods for generating skin |
US7575921B2 (en) | 1999-12-30 | 2009-08-18 | Vbi Technologies, L.L.C. | Spore-like cells and uses thereof |
WO2001051084A1 (en) * | 2000-01-14 | 2001-07-19 | Genentech, Inc. | Diagnosis and treatment of hepatic inflammatory disorders by inhibiting the binding of lfa-1 to icam-1 |
JP5113314B2 (ja) * | 2000-09-01 | 2013-01-09 | ザ センター フォー ブラッド リサーチ インク | 所望のコンホメーションで安定させた改変ポリペプチド及び該ポリペプチドの作製方法 |
WO2002057428A1 (en) | 2000-10-30 | 2002-07-25 | University Of Massachusetts | Isolation of spore-like cells from tissues exposed to extreme conditions |
ATE417858T1 (de) | 2002-02-05 | 2009-01-15 | Genentech Inc | Proteinaufreinigung |
EP1501369B1 (de) | 2002-04-26 | 2015-06-24 | Genentech, Inc. | Nichtaffinitätsreinigung von proteinen |
JP5401001B2 (ja) | 2002-09-11 | 2014-01-29 | ジェネンテック, インコーポレイテッド | 免疫関連疾患の治療のための新規組成物と方法 |
US7388079B2 (en) | 2002-11-27 | 2008-06-17 | The Regents Of The University Of California | Delivery of pharmaceutical agents via the human insulin receptor |
CA2523142A1 (en) * | 2003-04-23 | 2004-11-04 | Medarex, Inc. | Humanized antibodies to interferon alpha receptor-1 (ifnar-1) |
EP3095793B1 (de) | 2003-07-28 | 2020-03-25 | Genentech, Inc. | Verringerung des protein-a-auslaugens während einer affinitätschromatografie |
WO2005079515A2 (en) | 2004-02-19 | 2005-09-01 | The Cbr Institute For Biomedical Research, Inc. | Conformation specific antibodies |
ATE452147T1 (de) | 2004-02-19 | 2010-01-15 | Genentech Inc | Antikörper mit korrigierten cdr |
RU2006146939A (ru) * | 2004-06-09 | 2008-07-20 | Дженентек | Способ лечения кольцевидной гранулемы или саркоида |
US7662926B2 (en) | 2004-09-02 | 2010-02-16 | Genentech, Inc. | Anti-Fc-gamma receptor antibodies, bispecific variants and uses therefor |
US7655229B2 (en) | 2004-09-02 | 2010-02-02 | Chan Andrew C | Anti-FC-gamma RIIB receptor antibody and uses therefor |
JO3000B1 (ar) | 2004-10-20 | 2016-09-05 | Genentech Inc | مركبات أجسام مضادة . |
FR2902799B1 (fr) | 2006-06-27 | 2012-10-26 | Millipore Corp | Procede et unite de preparation d'un echantillon pour l'analyse microbiologique d'un liquide |
US8362217B2 (en) | 2006-12-21 | 2013-01-29 | Emd Millipore Corporation | Purification of proteins |
WO2008079302A2 (en) | 2006-12-21 | 2008-07-03 | Millipore Corporation | Purification of proteins |
US8569464B2 (en) | 2006-12-21 | 2013-10-29 | Emd Millipore Corporation | Purification of proteins |
ATE526017T1 (de) | 2007-01-22 | 2011-10-15 | Genentech Inc | Abscheidung von polyelektrolyten und reinigung von antikörpern |
LT3597659T (lt) | 2007-07-09 | 2023-05-10 | Genentech, Inc. | Disulfidinės jungties redukcijos prevencijos būdas gaminant polipeptidą rekombinantiniu būdu |
SI2215117T2 (en) | 2007-10-30 | 2018-04-30 | Genentech, Inc. | Purification of the antibody by cation exchange chromatography |
KR101855381B1 (ko) | 2008-04-09 | 2018-05-09 | 제넨테크, 인크. | 면역 관련 질병의 치료를 위한 신규한 조성물 및 방법 |
US8999702B2 (en) | 2008-06-11 | 2015-04-07 | Emd Millipore Corporation | Stirred tank bioreactor |
EP2145901B1 (de) | 2008-07-18 | 2012-11-14 | Technische Universität Braunschweig | Rekombinante anti-MUC1-Antikörper |
LT2848625T (lt) | 2008-08-14 | 2019-10-10 | Genentech, Inc. | Priemaišų pašalinimo būdai, panaudojant reziduojančio baltymo pakeitimą jonų mainų membraninės chromatografijos pagalba |
KR20110076918A (ko) | 2008-09-10 | 2011-07-06 | 제넨테크, 인크. | 단백질의 산화성 분해를 방지하기 위한 조성물 및 방법 |
WO2010074702A1 (en) | 2008-12-16 | 2010-07-01 | Millipore Corporation | Purification of proteins |
ES2749232T3 (es) | 2008-12-16 | 2020-03-19 | Emd Millipore Corp | Reactor de tanque agitado y procedimiento |
EP2400992B1 (de) | 2009-02-27 | 2015-07-22 | Genentech, Inc. | Verfahren und zusammensetzungen zur kennzeichnung von proteinen |
RU2639288C2 (ru) | 2009-08-11 | 2017-12-20 | Дженентек, Инк. | Получение белков в культуральных средах без глутамина |
CN108409829A (zh) | 2009-09-01 | 2018-08-17 | 弗·哈夫曼-拉罗切有限公司 | 通过改进的a蛋白洗脱增强的蛋白质纯化 |
KR102173873B1 (ko) | 2009-11-12 | 2020-11-04 | 브이셀 세라퓨틱스 인코포레이티드 | 포자를 닮은 세포들의 계군 및 그 용도 |
US20120309056A1 (en) | 2010-02-04 | 2012-12-06 | Leon Arnaud | Fed-batch process using concentrated cell culture medium for the efficient production of biologics in eb66 cells |
ES2722201T3 (es) | 2010-03-22 | 2019-08-08 | Hoffmann La Roche | Composiciones y procedimientos útiles para estabilizar formulaciones que contienen proteínas |
WO2011139718A1 (en) | 2010-05-03 | 2011-11-10 | Genentech, Inc. | Compositions and methods useful for reducing the viscosity of protein-containing formulations |
CN102892791B (zh) | 2010-05-17 | 2017-05-17 | Emd密理博公司 | 用于纯化生物分子的刺激响应性聚合物 |
MX343604B (es) | 2010-05-28 | 2016-11-11 | Genentech Inc | Disminuir nivel de lactato e incrementar producción de polipéptidos por regulación a la baja de la expresión de lactato dehidrogenasa y piruvato dehidrogenasa quinasa. |
ES2880802T3 (es) | 2010-06-24 | 2021-11-25 | Hoffmann La Roche | Composiciones y procedimientos para estabilizar formulaciones que contienen proteínas |
EP2603525A1 (de) | 2010-08-13 | 2013-06-19 | F.Hoffmann-La Roche Ag | Antikörper gegen il-1beta und il-18 zur behandlung von krankheiten |
WO2012030512A1 (en) | 2010-09-03 | 2012-03-08 | Percivia Llc. | Flow-through protein purification process |
US9814740B2 (en) * | 2010-12-21 | 2017-11-14 | Duke University | Methods and compositions combining immunotherapy with monocyte activation |
WO2012095514A1 (en) | 2011-01-14 | 2012-07-19 | Vivalis | Recombinant protein production system |
SG11201403437TA (en) | 2011-12-22 | 2014-07-30 | Genentech Inc | Ion exchange membrane chromatography |
US20140080180A1 (en) | 2012-03-27 | 2014-03-20 | Genentech, Inc. | Harvest operations for recombinant proteins |
KR102326359B1 (ko) | 2012-05-18 | 2021-11-12 | 제넨테크, 인크. | 고농도 모노클로날 항체 제제 |
WO2014100095A1 (en) | 2012-12-19 | 2014-06-26 | Genentech, Inc. | Methods and compositions for radiohalogen protein labeling |
FI3019240T3 (fi) | 2013-07-09 | 2024-05-30 | Annexon Inc | Anti-komplementtitekijä c1q -vasta-aineita ja niiden käyttöjä |
TWI685349B (zh) | 2013-07-16 | 2020-02-21 | 建南德克公司 | 利用pd-1軸結合拮抗劑及tigit抑制劑治療癌症之方法 |
PL3166401T3 (pl) | 2014-07-09 | 2021-01-25 | F. Hoffmann-La Roche Ag | Dostosowanie pH w celu poprawy wyników regeneracji banków komórek po rozmrożeniu |
JP6951246B2 (ja) | 2014-11-05 | 2021-10-20 | アネクソン,インコーポレーテッド | ヒト化抗補体因子C1q抗体及びその使用 |
ES2924071T3 (es) | 2015-09-02 | 2022-10-04 | Yissum Res Dev Co Of Hebrew Univ Jerusalem Ltd | Anticuerpos específicos para inmunoglobulina de células T humanas y dominio ITIM (TIGIT) |
BR112018005862A2 (pt) | 2015-09-25 | 2018-10-16 | Genentech, Inc. | anticorpos, anticorpos isolados, polinucleotídeo, vetor, célula hospedeira, método de produção do anticorpo, imunoconjugado, composição, usos dos anticorpos, métodos para tratar ou retardar a progressão de um câncer e de uma doença e para aumentar, potencializar ou estimular uma resposta ou função imune e kit |
IL296130A (en) | 2015-11-24 | 2022-11-01 | Annexon Inc | Anti-complement factor c1q fab fragments and their uses |
JP2019510517A (ja) | 2016-03-29 | 2019-04-18 | ジェルター, インコーポレイテッド | 細胞質内体積に対するペリプラズム体積の比率が0.5:1および10:1の間にあるグラム陰性細菌におけるタンパク質の発現 |
KR102579836B1 (ko) | 2016-12-22 | 2023-09-15 | 제넨테크, 인크. | 동결건조된 폴리펩타이드의 재구성 시간을 감소시키기 위한 방법 및 제제 |
US11180541B2 (en) | 2017-09-28 | 2021-11-23 | Geltor, Inc. | Recombinant collagen and elastin molecules and uses thereof |
BR112020025623A2 (pt) | 2018-07-03 | 2021-03-23 | Bristol-Myers Squibb Company | métodos de produção de proteínas recombinantes |
KR20210074341A (ko) | 2018-10-10 | 2021-06-21 | 베링거 인겔하임 인터내셔날 게엠베하 | 고밀도 생물 반응기 배양에서 막 기체 전달을 위한 방법 |
JP2022521840A (ja) | 2019-04-01 | 2022-04-12 | ジェネンテック, インコーポレイテッド | タンパク質含有製剤を安定化するための組成物および方法 |
WO2020210440A1 (en) | 2019-04-12 | 2020-10-15 | Geltor, Inc. | Recombinant elastin and production thereof |
KR20220039777A (ko) | 2019-08-01 | 2022-03-29 | 브리스톨-마이어스 스큅 컴퍼니 | 유가식 세포 배양에서 단백질 생산성을 개선시키는 방법 |
US20230357815A1 (en) | 2020-09-22 | 2023-11-09 | Bristol-Myers Squibb Company | Methods for increasing productivity of therapeutic proteins |
WO2023015234A1 (en) | 2021-08-05 | 2023-02-09 | Bristol-Myers Squibb Company | Cell culture methods for producing therapeutic proteins |
WO2023049687A1 (en) | 2021-09-21 | 2023-03-30 | Bristol-Myers Squibb Company | Methods of controlling the level of dissolved oxygen (do) in a solution comprising a recombinant protein in a storage container |
Family Cites Families (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
NZ236792A (en) * | 1990-01-19 | 1993-05-26 | Merck & Co Inc | Recombinant human anti-cd18 antibody, murine 1b4 heavy or light chain variable region, dna, vectors, mammalian host and pharmaceutical compositions |
US6096871A (en) * | 1995-04-14 | 2000-08-01 | Genentech, Inc. | Polypeptides altered to contain an epitope from the Fc region of an IgG molecule for increased half-life |
-
1997
- 1997-10-20 KR KR10-1999-7004671A patent/KR100532178B1/ko not_active IP Right Cessation
- 1997-10-20 EP EP04004941A patent/EP1516629B1/de not_active Expired - Lifetime
- 1997-10-20 PT PT97912841T patent/PT941344E/pt unknown
- 1997-10-20 DE DE200412000047 patent/DE122004000047I1/de active Pending
- 1997-10-20 DK DK04004941.3T patent/DK1516629T3/da active
- 1997-10-20 AT AT97912841T patent/ATE267257T1/de active
- 1997-10-20 EP EP97912841A patent/EP0941344B1/de not_active Expired - Lifetime
- 1997-10-20 DK DK97912841T patent/DK0941344T3/da active
- 1997-10-20 JP JP52464598A patent/JP3778945B2/ja not_active Expired - Lifetime
- 1997-10-20 WO PCT/US1997/019041 patent/WO1998023761A1/en not_active Application Discontinuation
- 1997-10-20 DE DE69729209T patent/DE69729209T2/de not_active Expired - Lifetime
- 1997-10-20 CA CA2272842A patent/CA2272842C/en not_active Expired - Lifetime
- 1997-10-20 IL IL13014397A patent/IL130143A0/xx active IP Right Grant
- 1997-10-20 AU AU49929/97A patent/AU731817C/en not_active Expired
- 1997-10-20 DE DE1997629209 patent/DE122004000047I2/de active Active
- 1997-10-20 ES ES97912841T patent/ES2221045T3/es not_active Expired - Lifetime
- 1997-10-27 ZA ZA979599A patent/ZA979599B/xx unknown
- 1997-11-04 AR ARP970105146A patent/AR008919A1/es active IP Right Grant
-
1999
- 1999-05-26 IL IL130143A patent/IL130143A/en not_active IP Right Cessation
-
2004
- 2004-11-10 LU LU91122C patent/LU91122I2/fr unknown
- 2004-11-12 NL NL300163C patent/NL300163I2/nl unknown
- 2004-12-10 FR FR04C0028C patent/FR04C0028I2/fr active Active
-
2005
- 2005-08-02 JP JP2005224609A patent/JP4309383B2/ja not_active Expired - Lifetime
-
2006
- 2006-05-11 IL IL175583A patent/IL175583A0/en not_active IP Right Cessation
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
DE69729209D1 (de) | Humanisierte anti-koerper gegen cd11a | |
NO955167D0 (no) | Monoklonalt anti- | |
ATE384125T1 (de) | Antikörper gegen cd-80 | |
NO20000852L (no) | Skrueseparator | |
DE69816798D1 (de) | Wiederverschliessbarer verschluss | |
FI961082A0 (fi) | Matkaviestin | |
ID21031A (id) | Kornea buatan | |
ID19056A (id) | Turunan 6-fenilpiridil-2-amina | |
DE69835304D1 (de) | Fluorierung mit Aminoschwefeltrifluoriden | |
DE69732654D1 (de) | Gewindeformender rohrverschluss | |
DE69710671D1 (de) | Schminkbehälter | |
DE69727334D1 (de) | Kopiergerät | |
DE59707742D1 (de) | Schliessvorrichtung | |
FI98105B (fi) | Mikroliuska-aaltoputkisiirtymä | |
DE69718660D1 (de) | Schliessvorrichtung | |
DE69505860D1 (de) | Komparator | |
NO963318D0 (no) | Sandströer | |
BR9711681A (pt) | Novos m-todos | |
KR960035141U (ko) | 파이프 분배기 | |
DE69732636D1 (de) | Monoklonaler antikörper gegen humanes mp52 | |
FI942951A0 (fi) | Uppvaermningsenhet foer bitumen | |
KR970021714U (ko) | 우산 수납형 도어 | |
KR970058280U (ko) | 통 | |
KR970053218U (ko) | 향주머니를 갖는 조화 | |
KR980000171U (ko) | 쥐잡이 통 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
R071 | Expiry of right |